Wedbush Morgan maintains an Outperform rating on Nektar Therapeutics (Nasdaq: NKTR), raises price target from $8 to $11.

Wedbush analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE